Shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) have earned a consensus rating of “Buy” from the thirteen brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $20.10.
Several research analysts have weighed in on the stock. Maxim Group set a $8.00 price target on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, April 11th. HC Wainwright set a $13.00 price target on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Friday, January 12th. BidaskClub raised shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 24th. Royal Bank of Canada increased their price target on shares of Inovio Pharmaceuticals from $11.00 to $14.00 and gave the company an “outperform” rating in a report on Thursday, March 15th. Finally, ValuEngine cut shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st.
In other news, CEO Jong Joseph Kim sold 103,750 shares of the firm’s stock in a transaction that occurred on Thursday, April 12th. The shares were sold at an average price of $5.14, for a total transaction of $533,275.00. Following the transaction, the chief executive officer now directly owns 2,395,557 shares of the company’s stock, valued at $12,313,162.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.40% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. MetLife Investment Advisors LLC bought a new position in shares of Inovio Pharmaceuticals during the fourth quarter worth approximately $150,000. Vident Investment Advisory LLC increased its holdings in shares of Inovio Pharmaceuticals by 95.3% during the fourth quarter. Vident Investment Advisory LLC now owns 291,713 shares of the biopharmaceutical company’s stock worth $1,205,000 after purchasing an additional 142,328 shares during the period. Teachers Advisors LLC increased its holdings in shares of Inovio Pharmaceuticals by 11.2% during the fourth quarter. Teachers Advisors LLC now owns 159,972 shares of the biopharmaceutical company’s stock worth $661,000 after purchasing an additional 16,104 shares during the period. Deutsche Bank AG increased its holdings in shares of Inovio Pharmaceuticals by 247.7% during the fourth quarter. Deutsche Bank AG now owns 449,708 shares of the biopharmaceutical company’s stock worth $1,856,000 after purchasing an additional 320,376 shares during the period. Finally, Tocqueville Asset Management L.P. bought a new position in shares of Inovio Pharmaceuticals during the fourth quarter worth approximately $218,000. 31.50% of the stock is currently owned by institutional investors.
Shares of INO stock traded down $0.16 on Wednesday, reaching $4.90. The stock had a trading volume of 766,950 shares, compared to its average volume of 1,320,553. The stock has a market cap of $458.95, a price-to-earnings ratio of -4.50 and a beta of 2.50. Inovio Pharmaceuticals has a 12 month low of $3.76 and a 12 month high of $9.86.
Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.06. The company had revenue of $8.80 million for the quarter, compared to analysts’ expectations of $9.13 million. Inovio Pharmaceuticals had a negative net margin of 208.92% and a negative return on equity of 66.07%. Inovio Pharmaceuticals’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.35) EPS. research analysts anticipate that Inovio Pharmaceuticals will post -1.07 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Inovio Pharmaceuticals Inc (INO) Given Average Recommendation of “Buy” by Brokerages” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://ledgergazette.com/2018/04/23/inovio-pharmaceuticals-inc-ino-given-average-recommendation-of-buy-by-brokerages.html.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.